An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)
Ahrens, M. Escudier, B. Haanen, J. Boleti, E. Gross-Goupil, M. Grimm, M. O. Negrier, S. Barthelemy, P. Gravis, G. Ivanyi, P.
Ahrens, M.
Escudier, B.
Haanen, J.
Boleti, E.
Gross-Goupil, M.
Grimm, M. O.
Negrier, S.
Barthelemy, P.
Gravis, G.
Ivanyi, P.
Citations
Altmetric:
Abstract
Authors
Ahrens, M.
Escudier, B.
Haanen, J.
Boleti, E.
Gross-Goupil, M.
Grimm, M. O.
Negrier, S.
Barthelemy, P.
Gravis, G.
Ivanyi, P.
Bedke, J.
Castellano, D.
Panic, A.
Mellado, B.
Maroto, P.
Rottey, S.
Zschabitz, S.
Florcken, A.
Bogemann, M.
Waddell, Thomas
Rodriguez, C. S.
Lorch, A.
Deckbar, D.
Hartmann, A.
Bergmann, L.
Escudier, B.
Haanen, J.
Boleti, E.
Gross-Goupil, M.
Grimm, M. O.
Negrier, S.
Barthelemy, P.
Gravis, G.
Ivanyi, P.
Bedke, J.
Castellano, D.
Panic, A.
Mellado, B.
Maroto, P.
Rottey, S.
Zschabitz, S.
Florcken, A.
Bogemann, M.
Waddell, Thomas
Rodriguez, C. S.
Lorch, A.
Deckbar, D.
Hartmann, A.
Bergmann, L.
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Ahrens M, Escudier B, Haanen J, Boleti E, Gross-Goupil M, Grimm MO, et al. An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST). Oncology Research and Treatment. 2022 Nov;45(SUPPL 3):101-2. PubMed PMID: WOS:000883051700235.